Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.60 |
| ▸ | CA1 | P00915 | 12/20 | 0.60 |
| ▸ | CA9 | Q16790 | 4/20 | 0.60 |
| ▸ | CA6 | P23280 | 3/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA5A | P35218 | 2/20 | 0.60 |
| ▸ | CA7 | P43166 | 2/20 | 0.60 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.60 |
| ▸ | PTGES2 | Q9H7Z7 | 6/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25465852 | 0.89 | CA2 (0.56) | CA2CA1CA9CA6CA12 | |
| SCHEMBL12139315 | 0.82 | ADRA1A (0.43) | CA2CA1CA9CA6CA12 | |
| SCHEMBL29932855 | 0.81 | CA2 (0.55) | CA2CA1CA9CA6CA12 | |
| SCHEMBL23135648 | 0.81 | ADRA2A (0.47) | CA2CA1CA9CA6CA12 | |
| SCHEMBL7512674 | 0.81 | TTR (0.42) | CA2CA1CA9CA6CA12 | |
| SCHEMBL7144287 | 0.79 | CA2 (0.49) | CA2CA1CA9CA6CA12 | |
| SCHEMBL30335715 | 0.78 | CA2 (0.67) | CA2CA1CA9CA6CA12 | |
| SCHEMBL3363295 | 0.78 | CA2 (0.67) | CA2CA1CA9CA6CA12 | |
| SCHEMBL25465864 | 0.77 | CA2 (0.55) | CA2CA1CA9CA6CA12 | |
| SCHEMBL1425352 | 0.75 | CA2 (1.00) | CA2CA1CA9CA6CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081759-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-2007788-A2 | HCV INHIBITORS | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-20070265281-A1 | Organic Compounds and Their Uses | COTTENS SYLVAIN | 2007-11-15 | — | — | US | disclosed |
| US-20070265281-A1 | Organic Compounds and Their Uses | COTTENS SYLVAIN | 2007-11-15 | — | — | US | disclosed |
| US-20070265281-A1 | Organic Compounds and Their Uses | COTTENS SYLVAIN | 2007-11-15 | — | — | US | disclosed |
| WO-2007121125-A2 | HCV INHIBITORS | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121125-A2 | HCV INHIBITORS | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265281-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CA2 1716/4885CA1 2516/4885CA9 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.